2018

May 23, 2018
Apogenix Provides Update on Clinical Development of Asunercept
 

2017

October 5, 2017
Apogenix Granted Orphan Designation by the European Commission for Asunercept to Treat Myelodysplastic Syndromes

May 29, 2017
Apogenix Granted PRIME Designation by European Medicines Agency for Asunercept to Treat Glioblastoma

April 26, 2017
Apogenix to Present at Three Upcoming International Conferences

April 11, 2017
Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie

March 20, 2017
Apogenix Presents Data on Novel Hexavalent TNF Receptor Agonists (HERA) at the Upcoming Annual Meeting of the American Association for Cancer Research (AACR)
 

 

2016

December 5, 2016
Apogenix Reports Final Phase I MDS Data at this Year's American Society of Hematology (ASH) Meeting 

November 4, 2016
Apogenix Reports Significant Progress in Collaboration with CANbridge

November 3, 2016
Apogenix Announces Oral Presentation on APG101 at Upcoming 58th American Society of Hematology (ASH) Meeting & Exposition

July 19, 2016
Apogenix Granted European Patent for the Use of APG101 in the Treatment of Myelodysplastic Syndromes

June 15, 2016
Apogenix Reports Topline Results from Phase I Trial in Myelodysplastic Syndromes with APG101

May 4, 2016
Apogenix to Present at Two Upcoming International Conferences

March 24, 2016
Preclinical Efficacy Data of Apogenix' APG101 in Myelodysplastic Syndromes (MDS) published in Oncotarget

February 16, 2016
Apogenix Receives €3 Million Grant for the Development of a Companion Diagnostic Test for Lead Immuno-Oncology Candidate APG101

January 14, 2016
Apogenix Strengthens U.S. Patent Position for Lead Immuno-Oncology Candidate APG101

January 7, 2016
Apogenix Receives First Milestone Payment from CANbridge Licensing Agreement and Signs Amendment to Include Taiwan

 

 

For press releases from previous years, please visit our archive.